Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment.

Oncotarget · 2016 · PMC5226582 · PMID 27385210

Europe PMC DOI

hedged sentence

0.0580

closest p · 1.2× alpha

0.0580

boldest claim

The sentences

a strong trendp=0.058so close (0.05 < p ≤ 0.1)

In the B16.F10 tumors, there was a strong trend towards a decrease of CD11b + Gr1 + MDSCs in the tumor tissue in the combination therapy group (p=0.058, Figure 3C ).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.